AstraZeneca Enhances Drug Discovery with Pelago Bioscience's CETSA® Assay

Pelago Bioscience offers high-throughput screening service based on CETSA^® - a transformative, label-free assay for target engagement quantification in physiologically relevant context. In this case study, the CETSA^® assay has been exemplified with AstraZeneca's screening of 500,000 compounds on a protein target, demonstrating superior hit rates and a six-month time-saving advantage.